FierceBiotechFierceBiotechResearchFierceBiotechITFierceVaccinesFiercePharmaFiercePharmaManufacturing   FierceHealthcare

Free Newsletter

About | View Sample | Privacy
Related Topics >> FDA | Phase II | heart disease

SPOTLIGHT: Stem cell trial approved


Osiris Therapeutics has been given a green light by the FDA to start a Phase II trial of Prochymal--a formulation of adult stem cells--for heart attack victims. Release


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceBiotech Email Newsletter:
Be the first to comment
More stories about FDA   Phase II   heart disease  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

To combat spam, please enter the code in the image.